Elanco Animal Health
Market Cap
US$9.9b
Last Updated
2019/08/25 01:03 UTC
Data Sources
Company Financials +
Executive Summary
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals.
Snowflake
Fundamentals
Fair value with moderate growth potential.
Risks
- Elanco Animal Health has significant price volatility in the past 3 months.
Similar Companies
Share Price & News
How has Elanco Animal Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-10.0%
NYSE:ELAN
-1.4%
US Pharmaceuticals
-1.6%
US Market
1 Year Return
n/a
NYSE:ELAN
-8.4%
US Pharmaceuticals
-3.0%
US Market
No trading data on ELAN.
No trading data on ELAN.
Share holder returns
| ELAN | Industry | Market | |
|---|---|---|---|
| 7 Day | -10.0% | -1.4% | -1.6% |
| 30 Day | -20.4% | -4.4% | -5.7% |
| 90 Day | -17.7% | -5.7% | 0.2% |
| 1 Year | n/a | -6.2%-8.4% | -0.8%-3.0% |
| 3 Year | n/a | 8.3%0.9% | 38.1%29.1% |
| 5 Year | n/a | 20.1%7.5% | 50.8%34.1% |
Price Volatility Vs. Market
How volatile is Elanco Animal Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Elanco Animal Health (NYSE:ELAN) Using Too Much Debt?2 months ago | Simply Wall St
Should You Be Worried About Elanco Animal Health Incorporated's (NYSE:ELAN) 0.9% Return On Equity?6 months ago | Simply Wall St
Should You Be Worried About Elanco Animal Health Incorporated's (NYSE:ELAN) 1.7% Return On Equity?Valuation
Is Elanco Animal Health undervalued based on future cash flows and its price relative to the stock market?
46%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Elanco Animal Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
Elanco Animal Health's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Elanco Animal Health is overvalued based on earnings compared to the US Pharmaceuticals industry average.
Elanco Animal Health is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Elanco Animal Health is poor value based on expected growth next year.
Price Based on Value of Assets
Elanco Animal Health is good value based on assets compared to the US Pharmaceuticals industry average.
Next Steps
Future Growth
How is Elanco Animal Health expected to perform in the next 1 to 3 years based on estimates from 10 analysts?
33.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Elanco Animal Health's revenue is expected to grow by 3.7% yearly, however this is not considered high growth (20% yearly).
Elanco Animal Health's earnings are expected to grow significantly at over 20% yearly.
Elanco Animal Health's revenue growth is positive but not above the United States of America market average.
Elanco Animal Health's earnings growth is expected to exceed the United States of America market average.
Elanco Animal Health's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Elanco Animal Health is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Elanco Animal Health performed over the past 5 years?
56.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Elanco Animal Health has delivered over 20% year on year earnings growth in the past 5 years.
Elanco Animal Health has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
Elanco Animal Health has become profitable in the last year making it difficult to compare the US Pharmaceuticals industry average.
Return on Equity
Elanco Animal Health has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Elanco Animal Health used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
Return on Capital Employed
Unable to establish if Elanco Animal Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
Next Steps
Financial Health
How is Elanco Animal Health's financial position?
Financial Position Analysis
Elanco Animal Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Elanco Animal Health's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Elanco Animal Health's level of debt (45.8%) compared to net worth is high (greater than 40%).
Unable to establish if Elanco Animal Health's debt level has increased without past 5-year debt data.
Debt is not well covered by operating cash flow (15%, less than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 6.1x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1x debt.
Next Steps
Dividend
What is Elanco Animal Health's current dividend yield, its reliability and sustainability?
0.60%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Unable to evaluate Elanco Animal Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Elanco Animal Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Elanco Animal Health has not reported any payouts.
Unable to verify if Elanco Animal Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Elanco Animal Health has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Elanco Animal Health's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Elanco Animal Health's salary, the management and board of directors tenure and is there insider trading?
0.9yrs
Average management tenure
CEO
Jeff Simmons (52yo)
0.0yrs
Tenure
US$5,379,245
Compensation
Mr. Jeffrey N. Simmons, also known as Jeff, serves as President, Chief Executive Officer and Director at Elanco Animal Health Incorporated. Mr. Simmons has served as the Senior Vice President at Eli Lilly ...
CEO Compensation Analysis
Jeff's remuneration is lower than average for companies of similar size in United States of America.
Jeff's compensation has increased in line with Elanco Animal Health recently becoming profitable.
Management Age and Tenure
0.9yrs
Average Tenure
49yo
Average Age
The average tenure for the Elanco Animal Health management team is less than 2 years, this suggests a new team.
Board Age and Tenure
0.4yrs
Average Tenure
60.5yo
Average Age
The average tenure for the Elanco Animal Health board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 7,750 |
| Max Price | US$32.39 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 20,000 |
| Max Price | US$31.43 |
| Entity | Individual |
| Role | Chief Accounting Officer VP & Chief Accounting Officer |
| Shares | 225 |
| Max Price | US$24.00 |
| Entity | Individual |
| Role | Senior Key Executive Executive VP of Elanco USA |
| Shares | 20,000 |
| Max Price | US$24.00 |
| Entity | Individual |
| Role | Head of Human Resources Executive Vice President of Human Resources |
| Shares | 2,500 |
| Max Price | US$24.00 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 22,000 |
| Max Price | US$24.00 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President of Manufacturing & Quality |
| Shares | 500 |
| Max Price | US$24.00 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 10,000 |
| Max Price | US$24.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 1,200 |
| Max Price | US$24.00 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 10,000 |
| Max Price | US$24.00 |
| Entity | Individual |
| Role | Chief Legal Officer Executive VP |
| Shares | 5,000 |
| Max Price | US$24.00 |
| Entity | Individual |
| Shares | 400 |
| Max Price | US$24.00 |
| Entity | Individual |
| Shares | 1,000 |
| Max Price | US$24.00 |
Ownership Breakdown
Management Team
Jeff Simmons (52yo)
President
- Tenure: 0.0yrs
- Compensation: US$5.38m
Sarena Lin (48yo)
Executive VP of Elanco USA
- Tenure: 0.6yrs
- Compensation: US$2.86m
Todd Young (47yo)
Executive VP & CFO
- Tenure: 0.8yrs
- Compensation: US$680.65k
Michael-Bryant Hicks (44yo)
Executive VP
- Tenure: 1.1yrs
Jim Meer (49yo)
VP & Chief Accounting Officer
- Tenure: 0.9yrs
Julie Lawless
Senior Vice President of Corporate Affairs & Administration
- Tenure: 0.0yrs
Dave Kinard (52yo)
Executive Vice President of Human Resources
- Tenure: 0.0yrs
- Compensation: US$1.55m
Dave Urbanek (53yo)
Executive Vice President of Manufacturing & Quality
- Tenure: 1.1yrs
- Compensation: US$1.88m
Jim Greffet
Head of Investor Relations
- Tenure: 0.0yrs
Chris Keeley
Senior VP & Chief Information Officer
- Tenure: 0.0yrs
Board Members
Dave Hoover (73yo)
Chairman of the Board
- Tenure: 1.3yrs
- Compensation: US$122.00k
Lawrence Kurzius (61yo)
Director
- Tenure: 0.9yrs
- Compensation: US$88.67k
Art Garcia (57yo)
Director
- Tenure: 0.3yrs
Denise Scots-Knight (60yo)
Director
- Tenure: 0.4yrs
J.P. Bilbrey (62yo)
Director
- Tenure: 0.4yrs
Jeff Simmons (52yo)
President
- Tenure: 0.0yrs
- Compensation: US$5.38m
Deborah Kochevar (62yo)
Director
- Tenure: 0.4yrs
Kirk McDonald (52yo)
Director
- Tenure: 0.4yrs
Mike Harrington (56yo)
Director
- Tenure: 0.9yrs
Kapila Anand (65yo)
Director
- Tenure: 0.9yrs
- Compensation: US$89.34k
Company Information
Elanco Animal Health Incorporated's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Elanco Animal Health Incorporated
- Ticker: ELAN
- Exchange: NYSE
- Founded: 1954
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.851b
- Shares outstanding: 373.00m
- Website: https://www.elanco.com
Number of Employees
Location
- Elanco Animal Health Incorporated
- 2500 Innovation Way
- Greenfield
- Indiana
- 46140
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ELAN | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Sep 2018 |
| 5EA | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 2018 |
Biography
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, su ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/25 01:03 |
| End of Day Share Price | 2019/08/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.